HomeBUSINESS
BUSINESS

Positive Update Out for Burosumab in Adult XLH: Kyowa Kirin
(Dec.6.2017)

Kyowa Hakko Kirin and its US partner Ultragenyx Pharmaceutical on December 4 gave a positive update on their PIII trial for the anti-FGF23 monoclonal IgG1 antibody burosumab (development code: KRN23) for the treatment of X-linked hypophosphatemia (XLH) in adults ...
(LOG IN FOR FULL STORY)